Chiesi Global Rare Diseases Announces Health Canada Approval of Elfabrio(R) (pegunigalsidase alfa) for Fabry Disease
PARMA, Italy and WOODBRIDGE, Ontario, Dec. 16, 2025 (GLOBE NEWSWIRE) — Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced the Health Canada approval of Elfabrio(R) (pegunigalsidase alfa) for the treatment of adults with Fabry disease. Elfabrio is […]